Home > Insider Trading > Filing (0001012975-14-000084)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1485003	Eleven Biotherapeutics Inc.	EBIO	Pharmaceutical Preparations (2834)	252025616

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1180428	J Mark Levin	29 Newbury Street, 3Rd Floor Boston MA 02116	Yes	No	Yes	No
1192595	I Robert Tepper	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1192603	P Kevin Starr	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1408591	Third Rock Ventures Lp	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1578973	Trv Gp, Llc	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No
1578976	Third Rock Ventures Gp, L.p.	29 Newbury Street, 3Rd Floor Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-02-11	3,267,716	$0.00	3,598,424	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	481,619	$0.00	4,080,043	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	127,077	$0.06	4,207,120	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	82,989	$0.00	4,290,109	No	4	C	Direct
Common Stock	Acquisiton	2014-02-11	551,482	$0.00	4,841,591	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2014-02-11	20,750,000	$0.00	3,267,716	$0.00
Common Stock	Series B Preferred Stock	Disposition	2014-02-11	3,058,281	$0.00	481,619	$0.00
Common Stock	Common Stock Warrant (right to purchase)	Disposition	2014-02-11	127,077	$0.00	127,077	$0.06
Common Stock	Common Stock Warrant (right to purchase)	Disposition	2014-02-11	82,989	$0.00	82,989	$0.06

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series A Preferred Stock converted automatically into Common Stock on a 6.350 for-one basis upon the closing of the initial public offering of Eleven Biotherapeutics, Inc. (the "Issuer") without payment of additional consideration and had no expiration date.
The shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P. ("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP, LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper") and, as such, each of TRV GP and TRV GP LLC, Levin, Starr and Tepper exercises shared voting and investment power over the shares held of record by TRV. Each of the filing persons disclaims beneficial ownership of the shares except to the extent of their pecuniary interest therein, if any.
The Series B Preferred Stock converted automatically into Common Stock on a 6.350 for-one basis upon the closing of the initial public offering of the Issuer without payment of additional consideration and had no expiration date.
The Warrant to purchase Common Stock was exercised automatically upon the closing of the Issuer's initial public offering and had an expiration date of June 28, 2018.
The Warrant to purchase Common Stock was exercised automatically upon the closing of the Issuer's initial public offering and had an expiration date of December 4, 2018.